TOP INTERVIEW

President, Kazuhiro Hatano

 

◆The background of Linical establishment and desire

 

Our company was established in June 2005 by nine members who was involved in new drug development in a major domestic pharmaceutical company.
I was involved in new drug development in Fujisawa (now Astellas) and it was a pleasure for me to work under Fujisawa’s company culture and atmosphere, therefore I felt great sadness when I learnt that the name “Fujisawa” will disappear.
This feeling encouraged me to be an entrepreneur of a CRO with a strong policy of “Inherit Fujisawa’s DNA”. This is how Linical was launched.
Sympathizing to our policy, Mr. Wolfgang Tinhof (ex-Fujisawa Europe CEO) as CEO of Linical Europe which is the largest subsidiary of Linical, Ms. Vivian Lee as CEO of Linical Taiwan (ex-Fujisawa Taiwan Vice General Manager) and Mr. Tae-Ro Lee as Auditor for Linical Korea (ex-Fujisawa Korea CEO) joined the Linical family.

 

◆Stock exchange listing, and to be a Global company

 

During my time at Fujisawa, I was involved in the development of an immunosuppressive agent that later became known as “one of the world-class drugs which was developed in Japan”. I intimately experienced the development process from clinical trial planning, approval, re-examination of post-marketing and the re-evaluation.
Taking advantage of those experiences in drug development, Linical started with a goal to become the strongest company in Japan. Our first entrusted pharmaceutical project began in December 2005 and this is when we were convinced that our goal will become reality.
We declared “public offering in three years” and in fact we were listed on the Mothers market in three years and four months from the date of company foundation. In 2013, we moved over to the First Section of the Tokyo Stock Exchange. In 2014, we expanded ourselves to Europe and started providing global clinical trial services. The growth of Linical will continue subsequently all over the world.

 

◆The Global outlook

 

The reason why we promote global expansion aggressively is because by conducting global studies simultaneously, new drugs that are in need now will be more swiftly approved in many countries without lag time which we believe will ultimately help more people who are suffering from diseases.
Previously, when I was working as a project leader for an immunosuppressive agent development in a pharmaceutical company, I was always feeling that “it is not only Japanese patients who are suffering from post-transplant rejection and autoimmune disease but also many other people in the world are suffering in the same way. If we could succeed in this drug development, we can eliminate this incurable disease which causes suffering in the world.”
Some of the projects which are currently carried out in our company are innovative new drug candidates which many people in the world are waiting for.
By conducting “Project X” like this as a development partner of pharmaceutical companies, we would like to witness and be a part of the birth of evolutional new drugs coming from Japan to the world.
Despite the fact that there are many excellent research results and technology in Japan, the environment of new drug development is still left partly as Galapagos syndrome (isolated development branch of a globally available product). Overcoming the language and time difference, if we could provide a high-quality service in Japan as well as to the entire world, we will become a one-of-a-kind global CRO. That is why we will continue to accelerate our global deployment further more.
We are a company who provides a service called new drug development. And our human resources who provide such professional services are our “human assets”.
What we hope for our “human assets” who have been entrusted of our future is to have a strong wish to perform clinical development and deliver better medicines to patients, not only in the developed countries where we are already present, but also in countries less fortunate.

 

◆Ideal human assets who Linical is seeking

 

In Linical we understand drug development as a science. We have many “human assets” who are experts of drug development which allows us to advise our customers in order to carry out the development process smoothly.
It is important to be able to add value as a professional not only for conducting the tasks with the instructions of our customer, but also understanding their needs by having good communication with our customers as well as the investigators.
Taking this into account, the people we would like to have work in our company should possess the following 3 qualities.
First, someone who can be at the forefront of this strong effort. Secondly, someone who keeps studying with passion and curiosity as a scientist. And lastly, someone who will not forget the feeling of gratitude because drug development consists with the support of the people around you. In addition, I hope people are sincere at work.
For example, your line manager asks you to complete a challenging task because she/he wants you to grow through the work.
I believe answering “I will do my best” instead of “I cannot” before you try, is considered more sincere.
You can always ask for help from your team members and leaders.  Most importantly, I want you to challenge yourself aggressively in the new work or difficult tasks that are given to you. In doing so, your growth and Linical’s growth will come together.
Last but not least, please keep in mind that there are endless opportunities for every employee in Linical. You may have a chance to be a global project manager who can work internationally and there is also a chance for everyone to become one of the management team members.
If you are willing to work globally as a drug development professional or if you are aiming to be a company management team member in the future, we look forward to receiving your application along with your challenging ambition!

PAGE TOP